Medtronic’s stent is intended to provide an off-the-shelf endovascular solution for treating a thoracoabdominal aortic aneurysm. Credit: Medtronic plc.

The US Food and Drug Administration (FDA) has granted breakthrough device designation to Medtronic’s minimally invasive Valiant TAAA Stent Graft System.

Valiant TAAA Stent Graft System is designed to repair a thoracoabdominal aortic aneurysm (TAAA). A TAAA causes swelling of the aorta, which extends from the chest into the abdomen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Commonly, TAAA affects the branch arteries supplying blood to various internal organs. The condition accounts for approximately 15% of all thoracic aneurysms.

The standard of care for TAAA is open surgery, which is complex and known to cause high morbidity and mortality. 40% of patients are not considered eligible for treatment, added Medtronic.

Medtronic’s stent is intended to provide an off-the-shelf endovascular solution for treating the condition. Currently, the device is undergoing five investigational device exemption trials in the US.

Medtronic aortic business vice-president and general manager John Farquhar said: “In addition to a high mortality rate for open surgical repair, physicians do not have good options when it comes to treatment for failed endograft.

“The FDA’s breakthrough designation for Valiant TAAA and our collaboration with leading physicians is an example of our willingness to take a courageous approach and challenge the limitations of current treatment options. This is about going further, together to improve patient outcomes.”

The breakthrough status will provide Medtronic priority review and interactive communication with the FDA regarding device development and clinical trial protocols until commercialisation decisions.

In May, the company also secured breakthrough designation for the use of Valiant Navion LSA branch thoracic stent graft system to provide left subclavian artery (LSA) coverage during thoracic endovascular aortic repair (TEVAR) procedures.

Furthermore, Medtronic has submitted a pre-market approval (PMA) supplement application to the US regulator for approval of InterStim Micro, a rechargeable version of its 20-year-old sacral neuromodulation device.

InterStim Micro treats overactive bladder, urinary urge incontinence, unobstructed urinary retention and faecal incontinence.